A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a CSL H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2010
At a glance
- Drugs AS03A; CSL 425
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics; Registrational
- 19 Feb 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Sep 2009 New trial record